Clearside Biomedical, Inc. Price & Performance (CLSD)

Clearside Biomedical's stock remains under close watch after analysts maintained price targets between $4 and $8, despite shares trading near $0.80. The company, preparing for pivotal Phase 3 trials of its wet AMD drug CLS-AX, recently posted a revenue beat but continues to face cash burn and high volatility.123

Short interest in Clearside Biomedical has dropped over 36% recently, signaling renewed investor confidence. This comes as the company reported a net loss of $34.4 million for 2024 and revenue of $1.7 million, down sharply from the prior year. Cash reserves are expected to fund operations into late 2025.435

Clearside Biomedical ended 2024 with $20 million in cash and a Q4 net loss of $7.3 million. Revenue fell due to fewer licensing payments, but management remains optimistic, citing ongoing collaborations and upcoming regulatory milestones in the U.S. and Asia-Pacific for its eye disease therapies.657